Omada Health
NASDAQ:OMDAMedical - Healthcare Information Services
+$0.13 today
- Market cap
- $817.04M
- Beta
- 2.09
- P/E (TTM)
- -162.6
- EPS (TTM)
- -$0.11
Volume 1.68M
Average 1.07M
OMDA Purchases of Investments
Cash used to buy marketable securities and other investments.
Omada HealthNASDAQ: OMDA
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments outflow grows to $0
Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.
Context
- Purchases of investments amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Purchases of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Purchases of Investments vs competitors
How OMDA compares with its peers on the latest reported figures
- OMDA's LTM Mar 2026 purchases of investments of $0 is the smallest of the 5 companies compared; the peer median is $22.5M.
- Purchases of investments amounts to 0.0% of revenue for OMDA, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $386.88M | +14.1% | — | 53.7% | |
| LTM Sep 2026 | $43.5M | -94.0% | +58.4% | 1.5% | |
| LTM Mar 2026 | $1.5M | -94.5% | — | 0.1% | |
| LTM Mar 2026 | $196K | -80.4% | -87.4% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding OMDA) | $22.5M | -87.2% | -14.5% | 0.8% | |
Competitors are the stored peer set for OMDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Depreciation & Amortization | 4.33M | 4.45M | 4.8M | 5.49M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.65M | 8.74M | 9.42M | 12.96M |
| Change in Working Capital | (9.15M) | (1.5M) | (6.57M) | 3.74M |
| Accounts Receivables | (3.93M) | (5.34M) | (8.81M) | (12.36M) |
| Inventory | (1.95M) | (74K) | 318K | (1.19M) |
| Accounts Payables | (4.99M) | (286K) | 399K | 6.29M |
| Other Working Capital | 1.73M | 4.2M | 1.52M | 11M |
| Other Non-Cash Items | 1.7M | 6.09M | 5.3M | 8.85M |
| Operating Cash Flow | (68.98M) | (49.74M) | (34.18M) | 18.25M |
| Capital Expenditures | (2.72M) | (2.92M) | (3.86M) | (1.32M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2M) | (2.51M) | (3.27M) | (4.51M) |
| Investing Cash Flow | (2.72M) | (2.92M) | (3.86M) | (5.83M) |
| Debt Repayment | (1.27M) | 963K | 0 | (30.96M) |
| Common Stock Issued | 1.74M | 1.76M | 3.33M | 169.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.27M | (2.54M) | (4.54M) | (5.71M) |
| Financing Cash Flow | 16.32M | 179K | (1.21M) | 133.22M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (55.38M) | (52.48M) | (39.25M) | 145.64M |
| Free Cash Flow | (71.7M) | (52.66M) | (38.04M) | 16.93M |
Omada Health
NASDAQ:OMDA
Intrinsic Alpha fair value
Locked
Current Price
$13.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.